The RADIANT-4 study met its primary end point with a median progression-free survival (PFS) of 11.0 months (mo) for EVE vs 3.9 mo for placebo (PBO; HR=0.48 [95% CI 0.35-0.67]; P < .00001) in patients (pts) with advanced, progressive, well-differentiated NET of lung or GI origin. A planned first interim OS analysis favored EVE but did not cross the boundary for significance (HR=0.64; 95% CI 0.40-1.05; P = .037). We report survival results from preplanned second interim OS analysis.
Background: The RADIANT-4 study met its primary end point with a median progression-free survival (PFS) of 11.0 months (mo) for EVE vs 3.9 mo for placebo (PBO; HR=0.48 [95% CI 0.35-0.67]; P < .00001) in patients (pts) with advanced, progressive, well-differentiated NET of lung or GI origin. A planned first interim OS analysis favored EVE but did not cross the boundary for significance (HR=0.64; 95% CI 0.40-1.05; P = .037). We report survival results from preplanned second interim OS analysis.
Methods: 302 pts with advanced, progressive, well-differentiated, nonfunctional lung/GI NET were randomized (2:1) to EVE (10 mg/d) or PBO, each with best supportive care. Pts were stratified by tumor origin, WHO performance status, and prior somatostatin analogue use. Primary end point was PFS; OS was the key secondary end point. OS was estimated using the Kaplan-Meier method and the treatment groups were compared using a one-sided log-rank test. The Lan-DeMets method with O'Brien-Fleming type stopping boundary was used to control the cumulative type I error rate. HR was estimated by a stratified Cox proportional hazards model.
Results:
By data cutoff (Nov 30, 2015) , 101 pts died; 66 of 205 (32%) in the EVE group and 35 of 97 (36%) in the PBO group. Median duration of study follow-up was 33.4 mo. EVE was associated with a 27% reduction in the estimated risk of death compared to PBO (HR=0.73; 95% CI 0.48-1.11; P = .071 [the P-value threshold to claim significance for OS was 0.001982]). Estimated survival rate at 2 years was 77% with EVE and 62% with PBO (Table 1) .
Conclusion:
The findings from this second interim OS analysis also suggested a trend for survival benefit with EVE, although statistical significance was not achieved. The final OS analysis will be performed when approximately 191 deaths have occurred. 
